Literature DB >> 17903235

Hepatic steatosis in HIV-HCV coinfected patients in France: comparison with HCV monoinfected patients matched for body mass index and HCV genotype.

L Castéra1, M A Loko, B Le Bail, P Coffie, V De Ledinghen, P Trimoulet, M Winnock, F Dabis, D Neau.   

Abstract

BACKGROUND: Significance of steatosis in HIV-HCV coinfection remains controversial. AIM: To compare the prevalence and predictors of hepatic steatosis between HIV-HCV and HCV patients matched for steatosis known determinants.
METHODS: A total of 564 HCV-naive patients undergoing liver biopsy were studied: 137 with HIV-HCV coinfection and 427 with HCV monoinfection, among whom 137 were matched for age, gender, body mass index and HCV genotype.
RESULTS: Steatosis of any grade (67.1% vs. 41.6%, P < 0.0001), mixed steatosis (55.4% vs. 21.1%, P < 0.0001), severe histological activity (A2-A3: 78.1% vs. 55.5%, P < 0.0001) and severe fibrosis (F3-F4: 33.1% vs. 15.3%, P < 0.0001) were significantly more common in coinfected than in matched monoinfected patients. In multivariate analysis, steatosis was associated only with severe histological activity [odds ratio (OR): 3.1 (95% CI: 1.3-7.1)] in coinfected patients and with elevated body mass index [OR; 1.3 (1.1-1.5)], HCV genotype 3 [OR: 5.6 (2.3-13.9)], severe histological activity [OR: 3.1 (1.3-7.3)] and severe fibrosis [OR: 4.7 (1.3-17.3)] in monoinfected patients.
CONCLUSIONS: Steatosis is significantly more common and severe in HIV-HCV coinfected than in HCV monoinfected French patients, even after matching for body mass index and HCV genotype. Steatosis is associated only with severe histological activity in coinfected patients and with previously reported factors in monoinfected patients, thus suggesting different underlying mechanisms.

Entities:  

Mesh:

Year:  2007        PMID: 17903235     DOI: 10.1111/j.1365-2036.2007.03533.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  14 in total

Review 1.  Novel Approaches to Targeting Visceral and Hepatic Adiposities in HIV-Associated Lipodystrophy.

Authors:  Phyllis C Tien
Journal:  Curr Atheroscler Rep       Date:  2015-12       Impact factor: 5.113

2.  Nonalcoholic fatty liver disease among HIV-infected persons.

Authors:  Nancy Crum-Cianflone; Angelica Dilay; Gary Collins; Dean Asher; Richard Campin; Sheila Medina; Zach Goodman; Robin Parker; Alan Lifson; Thomas Capozza; Mary Bavaro; Braden Hale; Charles Hames
Journal:  J Acquir Immune Defic Syndr       Date:  2009-04-15       Impact factor: 3.731

3.  Incidence and risk factors for steatosis progression in adults coinfected with HIV and hepatitis C virus.

Authors:  Tinsay A Woreta; Catherine G Sutcliffe; Shruti H Mehta; Todd T Brown; Yvonne Higgins; David L Thomas; Michael S Torbenson; Richard D Moore; Mark S Sulkowski
Journal:  Gastroenterology       Date:  2010-12-04       Impact factor: 22.682

4.  Hepatic steatosis in HIV-HCV coinfected patients receiving antiretroviral therapy is associated with HCV-related factors but not antiretrovirals.

Authors:  Valrie Martinez; Thi Dieu Ngan Ta; Zahra Mokhtari; Marguerite Guiguet; Patrick Miailhes; Marc-Antoine Valantin; Frderic Charlotte; Philippe Bertheau; Jean-Michel Molina; Christine Katlama; Eric Caumes
Journal:  BMC Res Notes       Date:  2012-07-09

5.  Adipose tissue and metabolic factors associated with steatosis in HIV/HCV coinfection: histology versus magnetic resonance spectroscopy.

Authors:  Alireza Ghotb; Susan M Noworolski; Erin Madden; Rebecca Scherzer; Aliya Qayyum; Jane Pannell; Linda Ferrell; Marion Peters; Phyllis C Tien
Journal:  J Acquir Immune Defic Syndr       Date:  2010-10       Impact factor: 3.731

6.  Pioglitazone for Hepatic Steatosis in HIV/Hepatitis C Virus Coinfection.

Authors:  Lindsay Matthews; David E Kleiner; Cheryl Chairez; Maryellen McManus; Mary Jane Nettles; Kira Zemanick; Caryn Gee Morse; Debra Benator; Joseph A Kovacs; Colleen Hadigan
Journal:  AIDS Res Hum Retroviruses       Date:  2015-08-24       Impact factor: 2.205

7.  Risk factors for fatty liver in the Multicenter AIDS Cohort Study.

Authors:  Jennifer C Price; Eric C Seaberg; Rachel Latanich; Matthew J Budoff; Lawrence A Kingsley; Frank J Palella; Mallory D Witt; Wendy S Post; Chloe L Thio
Journal:  Am J Gastroenterol       Date:  2014-03-18       Impact factor: 10.864

Review 8.  Fatty liver is associated with an increased risk of diabetes and cardiovascular disease - Evidence from three different disease models: NAFLD, HCV and HIV.

Authors:  Amedeo Lonardo; Stefano Ballestri; Giovanni Guaraldi; Fabio Nascimbeni; Dante Romagnoli; Stefano Zona; Giovanni Targher
Journal:  World J Gastroenterol       Date:  2016-11-28       Impact factor: 5.742

9.  The effects of Thiazolidinediones on metabolic complications and Lipodystrophy in HIV-infected patients.

Authors:  Jussi Sutinen
Journal:  PPAR Res       Date:  2008-12-01       Impact factor: 4.964

10.  Liver steatosis in Chinese HIV-infected patients with hypertriglyceridemia: characteristics and independent risk factors.

Authors:  Jiang Xiao; Ning Han; Di Yang; Hongxin Zhao
Journal:  Virol J       Date:  2013-08-14       Impact factor: 4.099

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.